S ymptom burden is a concept that encompasses the prevalence, severity, frequency, and impact of symptoms. 1 Cancer patients experience a range of physical and psychosocial symptoms. 2 A previous project by this research team demonstrated that cancer patients reported an average of 9 symptoms, with the specifc symptoms varying by cancer type. 3 Symptom burden was negatively correlated with patient quality of life. In the longitudinal component of that study, it was demonstrated that symptoms persisted over 1 year of follow-up and the inverse relationship with quality of life persisted as well. 4 Although other research has highlighted the dynamic nature of the symptom experience of cancer patients through the initial diagnosis and acute treatment phase, 5, 6 a large study of cancer survivors 2-5 years out of treatment found that 28% reported bothersome symptoms, but 82% of that subgroup noted inadequate symptom management. 7 Multiple symptoms persisting over time contribute to symptom burden.
Communication between health care providers (HCPs) and their patients is complicated. Research has shown that patients' communication decisions are afected by the level of trust patients have with the physician. [8] [9] [10] [11] Previous research suggests that symptoms are often underreported by patients. 12, 13 Several factors contribute to this phenomenon, such as patient stoicism, reluctance to report chronic symptoms, and tendency to report symptoms of recent onset and/or greater severity to HCPs. 9, 12, 14 Other research has focused on issues relevant to providers, such as time pressure in outpatient oncology clinic visits, a lack of confdence in symptom management skills, and an increasing presence of technology in the medical visit, among other factors. [15] [16] [17] [18] Also contributing to communication difculties are the misconceptions and attitudes among HCPs about how patients perceive symptoms, related to diferences between the HCP and patient in gender, cultural background, and age. 19 Previous research has suggested that nurses and patients demonstrate stronger agreement on symptoms than do physicians and patients, which has been attributed to nurses having more frequent and longer encounters with patients. 20, 21 Te existing research on symptom concordance is characterized by methodological difculties. Most previous research on concordance used retrospective analysis 16, 17, 23 and some have not used patient-physician dyads.
14 Frequently, diferent assessment tools are used for patients and for clinicians or the timing of the assessment is diferent, either of which make it difcult to determine whether discordance in symptom reporting is perhaps a methodological phenomenon. 21 Because of the complexity of symptoms that cancer patients experience and the association of symptoms with quality of life, it is important that HCPs are able to accurately identify the symptoms of their patients. Tis study addresses previous methodological difculties by prospectively examining agreement between patients and HCPs on identifying the symptoms that the patient endorses at the time of an outpatient clinic visit, using the same measurement tool. Te objectives of this study are to examine the concordance between HCPs' and patients' identifcation of symptoms and to determine how demographic and clinical variables interact with this concordance.
Methods

Participants
Patients of 3 oncology outpatient clinics at a National Cancer Institute-designated comprehensive cancer center in the Midwest of the United States provided data for this observational study. Te patients were recruited when they presented for an appointment with their medical oncologist or nurse practitioner. Patients were eligible to participate in the study if they were at least 18 years old; were diagnosed with cancer 3 months or more before the day of consent; had cancer of stage I, II, III, or IV; and were able to speak and read English. Patients were not eligible for the study if they were impaired by a psychiatric or cognitive disorder that limited their ability to give consent or communicate with their medical provider about symptoms. Eligible patients were identifed from the clinic schedule by the oncology team in advance and approached in the clinic waiting room before their appointment.
Procedures
Te study was reviewed and approved by the Protocol Review and Monitoring Committee of the cancer center and the Human Research Protection Ofce of the associated university. Eligible patients were approached in the waiting room by a research assistant who explained the study and sought their consent to participate. Patients were informed about the study and gave written consent if they agreed to participate. Consenting patients completed the study measures on paper while they waited for their clinic appointment. Te process of flling out the pre-visit measures took about 15 minutes. Te research assistant informed the HCPs of a patient's consent to participate in the study before their contact with the patient.
After the completion of the pre-visit measures, the patient's regular clinic visit proceeded. Patients were seen by all 3 HCPs or some combination of physicians (MD), nurse practitioners (NP), and nurse coordinators (NC). Immediately after the clinic visit, the HCPs who saw the patient completed a symptom survey in which they recorded the patient's symptoms. On the patients' symptom measure and the HCPs' symptom measure, the No choice was the default response.
Several questions about symptom communication were asked of patients. Before the clinic visit, they were asked which symptoms they planned to discuss. After the visit, they were asked about whether or not they discussed symptoms in the visit and the reasons for their behavior. Te HCPs were asked which symptoms were discussed during the clinic visit. Tese questions about communication are not addressed in this paper. Charlson Comorbidity Index: a measure of overall medical comorbidity. 24 Te CCI score range is 0-38, with higher scores indicating greater comorbidity.
Measures
25 an abbreviated version of the Memorial Symptom Assessment Survey, 23 measuring patients' experience with 32 symptoms over the previous week. Tis tool has been validated with oncology populations and has an alpha reliability of 0.83-0.88. 26, 5 On the MSAS-SF, patients reported symptoms they experienced in the previous week. For the purpose of this comparison, only the presence of symptoms (Yes/No) was used. In addition, the HCPs were provided a list of symptoms (taken from the MSAS-SF), and indicated which symptoms the patient had (Yes/No).
Data analysis
We used Cohen's kappa coefcient with a 95% confdence interval to evaluate concordance between diferent pairs (Patient [Pt]-MD, Pt-NP, Pt-NC) for each of the symptoms. Te patient responses were used as the standard against which the HCP symptom responses were checked for matches. We examined whether the degree of concor-dance on all symptoms for the diferent patient-HCP pairs was variable by type of cancer, age of patient, sex, comorbidity score, and stage of cancer.
An overall kappa, which combined concordance across all symptoms, was calculated for each patient-HCP pair with a 95% confdence interval. Te test for homogeneity of kappas between the pairs showed no signifcant diference (P = .116), so we calculated a unifed kappa between the combined HCP groups and the patients (Pt-HCP) for all symptoms, again with a 95% confdence interval. Tis is a more generous estimation of concordance because it assumes concordance if there is agreement between any of the 3 HCPs and the patient on each symptom; thus, the unifed kappa does not discriminate among the HCPs and allows the combined HCP group 3 times the chance to match with the patient. For more detailed examination of concordance for the 6 most prevalent symptoms, we used the physician results as representative of the HCPs. Finally, we calculated sensitivity, specifcity, and positive predictive value for Pt-MD matching for the top 6 symptoms. All statistical tests are two-sided at a signifcance level of .05. Te statistical analysis was conducted with SAS9.2. Table  1 describes the interpretation of the kappa 27 used in this study.
Results
Overall, we approached 125 patients about participating in the study and of those, 103 consented to participate (82%). Nine of the 103 patients dropped out after consenting or were found to be ineligible. Te data from these 9 patients were excluded; thus there were 94 patient participants (75% of those approached about the study) who completed the study measures. Table 2 shows the demographic and clinical data for the patient participants. Te participants attended clinics that treat 1 of 3 cancer types: breast (n = 32), gastrointestinal (n = 35), and lung (n = 27). Overall, the patient sample was primarily white and predominantly female. Tere were more patient participants with stages III or IV cancer than with early-stage disease. Tree MDs, 3 NPs, and 4 NCs participated in the study by completing the HCP symptom report.
Te maximum number of symptoms reported by patients, MDs, NPs, and NCs were 27, 11, 14, and 7 symptoms, respectively. Te minimum number was 0 for all 4 groups. Te patients reported 9.52 symptoms on average (SD, 6.10; Table 2 ). Te MDs reported a mean of 3.22 (SD, 2.35) symptoms; NPs 3.86 (SD, 3.16); and NCs 2.04 (SD, 2.08). We found no signifcant demographic or clinical factors related to concordance for symptoms.
Te summary kappa values for the Pt-MD, Pt-NP, and Pt-NC pairs across all 32 symptoms were 0.27, 0.29, and 0.19, respectively. As we noted in the data analysis description, we determined that there was no signifcant diference among the 3 pairs (P = .116), 25 so we examined Pt-unifed HCP (combining the results for all HCPs) kappa values for the most prevalent symptoms by patient report. Te 6 most prevalent symptoms were: lack of energy, pain, worrying, feeling sad, feeling nervous, and cough. Table 3 presents all symptoms with both the Pt-HCP kappa value and the Pt-MD kappa value (as representative of the individual pairs) for each symptom. Using the Landis and Koch interpretation of the kappa coefcient, 28 the highest level of agreement occurred with the symptom "problems with urination," which was also the least prevalent symptom (Table 1) . Other than this symptom, the highest level of concordance was in the moderate range. Te lowest unifed kappa value was for "problems with sexual interest/activity," which was ranked 27th by prevalence. Of the most prevalent symptoms, the unifed kappa values fell in the fair to moderate range. Table 4 presents the most prevalent symptoms for the 3 cancer groups. Table 4 also examines the sensitivity, specifcity, and positive predictive value (PPV) for physicians (as representative of the HCPs) in matching with their patients for the 6 most prevalent symptoms. Overall, the physicians displayed a 36.2% PPV in identifying these symptoms. Te concordance for the top 6 symptoms indicates greater sensitivity than specifcity; suggesting physicians were more prone to making false positive predictions than false negatives. (Tis is further supported by the data shown in the cross tabs in Table 5 .) Of the top 6 symptoms, pain had the highest PPV, indicating that agreement was best with this symptom. We used the crosstabs method for more detailed examination of the concordance between the patients and HCPs. Table 5 depicts the 4 diferent types of "matches" between the patient and physician (as representative of the HCPs), extending the data in Table 4 . When both the patient and physician indicate the same status for the symptom (ie, Yes/Yes or No/No), then there is concordance in the match, whereas mismatches (Yes/No and No/ Yes) indicate discordance. In Table 5 , the distribution for these 4 kinds of matches is shown for the Pt-MD pairs for the 6 most prevalent symptoms. Most of the concordant matches were those in which both the patient and the physician indicated a No for the symptom. Between the 2 kinds of discordance, the one in which the physician indicated a Yes and the patient indicated a No for the symptom was more common than the other (in which the patient indicated Yes and the physician indicated No). In fact the MD:No-Pt:Yes mismatches -false negatives -were the least prevalent of the 4 types of matches for these 6 symptoms. Furthermore, the MD:Yes-Pt:No mismatches were more common than the MD:No-Pt:Yes mismatches. Tese results also support that physicians' identifcation of patients' symptoms was more sensitive than specifc, with more false positive errors.
Discussion
High symptom burden for cancer patients has implications for clinical practice and patients' wellbeing. Tis study is consistent with others in showing that the most prevalent symptoms patients experience vary by cancer type. 3, 29 Te patients in this study, on average, reported experiencing 9.52 symptoms, which is also consistent with previous data. 3 We found no demographic or clinical factors related to patient-provider symptom concordance. Tis may suggest that symptom awareness is not a function of sex, race, or age; although there have Pt-MD, patient-physician been other fndings suggesting that symptom awareness is related to socioeconomic and demographic factors such as age and race. 27, 31 Our sample may not have been large enough to detect the impact of demographic or clinical variables on symptom agreement. Alternatively, the lack of association may relate to an unmeasured intrinsic variable in the patient-provider interaction in this clinical setting. Nevertheless, this result suggests concordance on symptoms is not related to a particular subset of patients.
In general, we found fair to moderate symptom agreement between HCPs and oncology patients by unifed Kappa scores; however, the level of agreement did not differ by provider type. Although some research has suggested that nurses' ratings of patients' symptoms match patients' ratings more closely than physicians' ratings do, 21, 32 our results do not support a diference by provider type. Te results suggest that there are communication challenges for this patient population, which is a problem because previous studies have documented benefts of good physicianpatient communication, such as increasing a patient's ability to cope with disease and satisfaction with care, enhancing informed consent and cooperation between patient and HCP, and decreasing HCPs' risk for burnout and the probability of facing malpractice litigation. 18, 33, 34 Owing to the high symptom burden in oncology, good communication seems critical to patient outcomes.
Some have questioned whether clinician reporting of patients' symptoms can ever be reliable. 35 Indeed, there are a number of possible explanations for the suboptimal patient-provider symptom agreement found in this study, some of which have been noted in the Introduction for this paper. In this study, HCPs were aware which patients were participating in the study and learned of patient participation prior to seeing the patient in clinic; therefore, they may have attended more to patients' symptoms, suggesting that our low concordance rates may be infated compared to usual practice. Te present results could also be indicative of patients' reluctance to share some complaints or symptoms with their HCPs, as has been suggested in other studies 14, 21, 36 Alternatively, it may be that some patients fail to disclose symptoms in order to seem as if they are getting better, as a way to convey that the HCPs' eforts have been successful. 37 Because symptom reporting is a social interaction, patient reporting could be afected by social desirability efects or impression management. Previous research has suggested that patients tend to highlight physical symptoms and underreport psychological symptoms 38, 39 or minimize symptoms to avoid being perceived as a complainer. 40, 41 Te agreement mismatch that was most common among the 6 most prevalent symptoms was that the physician wrongly ascribed the symptom to the patient. Te other type of mismatch -not recognizing symptoms the patient is experiencing -may be less surprising given previous fndings about patients underreporting symptoms. 11, 12 Laugsand and colleagues 42 found that HCPs underesti- 43 Te results in the present study may indicate that HCPs need to use terminology that is understood by their patients and encourage patient reporting of symptoms.
Te results of this study demonstrate variability in agreement across symptoms. Some symptoms typical of cancer or of cancer treatment (mouth sores, weight loss) were characterized by worse agreement, whereas others were not (nausea, diarrhea, constipation). Xiao and colleagues 44 suggested that concordance is better with "observable" symptoms, but that does not seem consistent with the present results. Basch and colleagues 45 indicated that physicians focus on more serious symptoms or those associated with clinical outcomes. In the present study, pain was the second most prevalent symptom and had relatively better agreement. Tis fnding may refect improved eforts at assessment of pain (pain as the "ffth vital sign"). 46 Alternatively, pain is a symptom that providers may feel more confdent about treating, whereas other symptoms may be more recalcitrant (ie, weight loss, oral ulcers). Perhaps providers more consistently question patients about symptoms for which efective treatment exists.
Te study has limitations, including the use of a small convenience sample size drawn from 3 specialty oncology outpatient clinics, which limits the generalizability of the results to other types of cancer. Only 75% of eligible patients agreed to participate in the study, and no symptom information was available on those patients who declined to participate. Terefore, these results may under-or overestimate symptom concordance. Tere were more female than male participants, largely because of the inclusion of a breast cancer clinic. Te distribution of cancer stage was weighted toward stages III and IV, which likely contributed to a higher number of symptoms. Finally, agreement on symptoms might have been better if patients had reported symptoms after the clinic visit, when the HCPs reported symptoms; however, data was collected on the same day in the same relative time frame.
In our next paper, we plan to examine the data about communication collected for this study. It seems that the patient-provider relationship, particularly in regard to efective communication about symptoms, is an area in need of clinical innovation. 47 Areas for future research include exploration of methods for measuring concordance between HCPs and patients, the impact of power diferential on the quality of communication, the efect of time constraints on the patientprovider interaction, and the role of serial prompting in assessment of symptoms. High symptom burden for cancer patients is an important concern with implications for clinical practice and the clinician-patient relationship. Te degree of symptom burden for patients and the generally weak agreement between patients and HCPs demonstrate the need for improved communication about symptoms in the oncology clinic. 
